phosphatase inhibitor buffer Search Results


lysis buffer supplemented protease inhibitor cocktail  (Nacalai)
90
Nacalai lysis buffer supplemented protease inhibitor cocktail
Lysis Buffer Supplemented Protease Inhibitor Cocktail, supplied by Nacalai, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lysis buffer supplemented protease inhibitor cocktail/product/Nacalai
Average 90 stars, based on 1 article reviews
lysis buffer supplemented protease inhibitor cocktail - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
whole cell lysis assay kgp 250-2100  (Keygen Biotech)
90
Keygen Biotech whole cell lysis assay kgp 250-2100
Whole Cell Lysis Assay Kgp 250 2100, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/whole cell lysis assay kgp 250-2100/product/Keygen Biotech
Average 90 stars, based on 1 article reviews
whole cell lysis assay kgp 250-2100 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa buffer containing protease and phosphatase inhibitors  (GenDEPOT)
90
GenDEPOT ripa buffer containing protease and phosphatase inhibitors
Ripa Buffer Containing Protease And Phosphatase Inhibitors, supplied by GenDEPOT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa buffer containing protease and phosphatase inhibitors/product/GenDEPOT
Average 90 stars, based on 1 article reviews
ripa buffer containing protease and phosphatase inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
tris lysis buffer containing phosphatase inhibitors i and ii and protease inhibitor  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC tris lysis buffer containing phosphatase inhibitors i and ii and protease inhibitor
Tris Lysis Buffer Containing Phosphatase Inhibitors I And Ii And Protease Inhibitor, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tris lysis buffer containing phosphatase inhibitors i and ii and protease inhibitor/product/Meso Scale Diagnostics LLC
Average 90 stars, based on 1 article reviews
tris lysis buffer containing phosphatase inhibitors i and ii and protease inhibitor - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
immunoprecipitation buffer  (Bimake Inc)
90
Bimake Inc immunoprecipitation buffer
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Immunoprecipitation Buffer, supplied by Bimake Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunoprecipitation buffer/product/Bimake Inc
Average 90 stars, based on 1 article reviews
immunoprecipitation buffer - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa buffer supplemented with protease/phosphatase inhibitors b15001  (Biomark Inc)
90
Biomark Inc ripa buffer supplemented with protease/phosphatase inhibitors b15001
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Ripa Buffer Supplemented With Protease/Phosphatase Inhibitors B15001, supplied by Biomark Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa buffer supplemented with protease/phosphatase inhibitors b15001/product/Biomark Inc
Average 90 stars, based on 1 article reviews
ripa buffer supplemented with protease/phosphatase inhibitors b15001 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
lysis buffer containing 1% protease inhibitor cocktail  (Beijing CWBio)
90
Beijing CWBio lysis buffer containing 1% protease inhibitor cocktail
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Lysis Buffer Containing 1% Protease Inhibitor Cocktail, supplied by Beijing CWBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lysis buffer containing 1% protease inhibitor cocktail/product/Beijing CWBio
Average 90 stars, based on 1 article reviews
lysis buffer containing 1% protease inhibitor cocktail - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa buffer supplemented with a phosphatase inhibitor  (Beijing Solarbio Science)
90
Beijing Solarbio Science ripa buffer supplemented with a phosphatase inhibitor
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Ripa Buffer Supplemented With A Phosphatase Inhibitor, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa buffer supplemented with a phosphatase inhibitor/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
ripa buffer supplemented with a phosphatase inhibitor - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa buffer containing protease and phosphatase inhibitors  (Epizyme Inc)
90
Epizyme Inc ripa buffer containing protease and phosphatase inhibitors
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Ripa Buffer Containing Protease And Phosphatase Inhibitors, supplied by Epizyme Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa buffer containing protease and phosphatase inhibitors/product/Epizyme Inc
Average 90 stars, based on 1 article reviews
ripa buffer containing protease and phosphatase inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa lysis buffer supplemented with 1% protease inhibitor and 1% phosphatase inhibitor  (ATTO Corp)
90
ATTO Corp ripa lysis buffer supplemented with 1% protease inhibitor and 1% phosphatase inhibitor
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Ripa Lysis Buffer Supplemented With 1% Protease Inhibitor And 1% Phosphatase Inhibitor, supplied by ATTO Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa lysis buffer supplemented with 1% protease inhibitor and 1% phosphatase inhibitor/product/ATTO Corp
Average 90 stars, based on 1 article reviews
ripa lysis buffer supplemented with 1% protease inhibitor and 1% phosphatase inhibitor - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ripa buffer containing phosphatase inhibitor, protease inhibitor 125 u benzonase  (Yeasen Biotechnology)
90
Yeasen Biotechnology ripa buffer containing phosphatase inhibitor, protease inhibitor 125 u benzonase
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Ripa Buffer Containing Phosphatase Inhibitor, Protease Inhibitor 125 U Benzonase, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa buffer containing phosphatase inhibitor, protease inhibitor 125 u benzonase/product/Yeasen Biotechnology
Average 90 stars, based on 1 article reviews
ripa buffer containing phosphatase inhibitor, protease inhibitor 125 u benzonase - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cell extraction buffer containing protease phosphatase inhibitors  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC cell extraction buffer containing protease phosphatase inhibitors
METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) <t>Co-immunoprecipitation</t> analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.
Cell Extraction Buffer Containing Protease Phosphatase Inhibitors, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell extraction buffer containing protease phosphatase inhibitors/product/Meso Scale Diagnostics LLC
Average 90 stars, based on 1 article reviews
cell extraction buffer containing protease phosphatase inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) Co-immunoprecipitation analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.

Journal: International Journal of Oncology

Article Title: N6-methyladenosine upregulates miR-181d-5p in exosomes derived from cancer-associated fibroblasts to inhibit 5-FU sensitivity by targeting NCALD in colorectal cancer

doi: 10.3892/ijo.2022.5304

Figure Lengend Snippet: METTL3-dependent m 6 A modification regulates DGCR8 processing of miR-181d-5p. (A) Co-immunoprecipitation analysis of DGCR8. (B) Immunoprecipitation of DGCR8 in METTL3-overexpressing cells. (C) Expression of miRNAs in exosomes derived from METTL3-overexpressing or METTL3-silencing CAFs. (D) Expression of pri-miR-181d, pre-miR-181d and miR-181d-5p and (E) the levels of pri-miR-181d-5p m 6 A in METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. (F) Analysis of pri-miRNA binding to DGCR8. (G) Analysis of pri-miRNAs m 6 A modification. (H and I) miR-181d-5p levels in CRC cells treated with exosomes derived from METTL3-overexpressing or METTL3-silencing lentivirus-transduced CAFs. All experiments were performed in triplicate. * P<0.05, ** P<0.01, *** P<0.001. METTL, methyltransferase like; m 6 A, RNA N6-methyladenosine; DGCR8, DiGeorge Syndrome Critical Region 8; miR/miRNA, microRNA; CAFs, cancer-associated fibroblasts; pri, primary; pre, precursor; sh, short hairpin; NC, negative control; CAFs-exo, primary CAFs.

Article Snippet: Cells were lysed using immunoprecipitation buffer (containing 1 mM DTT, 100 mmol/l NaCl and 1 mM MgCl 2 ) and protease inhibitor cocktails ( Bimake.com ).

Techniques: Modification, Immunoprecipitation, Expressing, Derivative Assay, Binding Assay, Negative Control